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The success of adoptive T cell-based immunotherapy
(ACT) in cancer is limited in part by the accumulation
of myeloid-derived suppressor cells (MDSC), which
block several T cell functions, including proliferation
and expression of effector mediators. Paradoxically, inhi-
bition of CD8+ T cell differentiation during the pre-
ACT phase also showed to increase anti-tumor efficacy.
Thus, we aimed to determine the effect of MDSC on
T cell differentiation and on ACT efficacy after in vitro
conditioning of CD8+ T cells. Results indicate that
MDSC block the differentiation of CD8+ T cells into
effector cells, without altering their activation status,
production of IL-2, or signaling through the T cell
receptor. Moreover, culturing of CD8+ T cells in the
presence of MDSC resulted in an increased ACT anti-
tumor activity and elevated frequency and IFNg produc-
tion after transfer onto tumor-bearing mice. Additional
findings confirmed that undifferentiated CD62L+ T cells
mediated the enhanced anti-tumor activity triggered by
MDSC-exposed T cells. Mechanistic studies showed that
MDSC restricted de novo protein synthesis and activity
of mechanistic target of rapamycin (mTOR) in T cells.
Silencing of the negative mTOR regulator tuberous
sclerosis complex 2 restored mTOR activity in T cells
co-cultured with MDSC, but resulted in T cell apopto-
sis. Thus, our results indicate that culturing of CD8+
T cells in the presence of MDSC improves their anti-
tumor efficacy, frequency, and function after ACT possibly
through inhibition of mTOR signaling. Continuation of
this research will enable the development of novel strate-
gies to enhance the efficacy of ACT in cancer.
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